Liraglutide
FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
0.6 – 3 mg
0.6 mg
Week 1
1.2-1.8 mg
Ongoing
3.0 mg
Ongoing
Compound profile
Scientific & efficacy data
Weight Management
Peptide profile
Strong human trials
Liraglutide
0.6 mg · Once daily
Molecular formula
C172H265N43O51
- Mol. weight
- 3,751 Da
- CAS number
- 204656-20-2
- PubChem
- 16134956
- Developed · 1997 (entered clinical development); FDA approved 2010 (Victoza), 2014 (Saxenda)
- Novo Nordisk Research Team
Novo Nordisk A/S
Amino acid sequence
H-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-C16 palmitateWeight Management
Liraglutide is one of the first FDA-approved anti-obesity medications, promoting 5–10% body weight loss at the 3.0 mg dose through central appetite suppression and delayed gastric emptying — with 61.5% of patients achieving clinically meaningful ≥5% weight loss in the SCALE program
Metabolic
Provides comprehensive metabolic improvement including HbA1c reduction of 0.9–1.6%, glucose-dependent insulin secretion, glucagon suppression, improved lipid profiles, and modest blood pressure reduction — addressing multiple cardiovascular risk factors simultaneously
Healing & Recovery
Demonstrated landmark cardiovascular protection in the LEADER trial — 13% MACE reduction, 22% CV mortality reduction, 11% MI reduction, and 12% stroke reduction over 3.5–5 years of follow-up in 9,340 high-risk type 2 diabetes patients
Dosing
How much do I take?
0.6 mg, titrated to 3.0 mg · once daily
0.6 – 3 mg
Once daily
Covers all 3 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for type 2 diabetes patients with hba1c >7% requiring both glycemic control and weight management & obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy
Best for
Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
Liraglutide is particularly well-suited for individuals focused on type 2 diabetes patients with hba1c >7% requiring both glycemic control and weight management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
Liraglutide is particularly well-suited for individuals focused on obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
Liraglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile
Liraglutide is particularly well-suited for individuals focused on patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Liraglutide with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Subcutaneous injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications.
Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare.
Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.
Liraglutide safety derives from LEAD Phase 3 diabetes trials (2008-2009) enrolling thousands of patients, SCALE obesity trials (2013-2014), and decades of post-marketing surveillance.
Published in New England Journal of Medicine and Diabetes Care, these studies establish favorable cardiovascular outcomes and weight reduction with well-characterized adverse event profiles. Regulatory oversight by FDA and EMA continues monitoring thyroid-related safety signals.
Common side effects · experienced by some users
Nausea
Most frequent adverse effect (20–40% incidence), typically dose-dependent and most pronounced during the first weeks of therapy and dose escalation. Generally mild to moderate and transient.
Management: Gradual dose titration per prescribing schedule. Eat smaller, more frequent meals. Avoid high-fat or very large meals. Most patients develop tolerance within 4–8 weeks.
Diarrhea
Occurs in 15–20% of patients, usually mild to moderate in severity. Related to GLP-1 receptor-mediated effects on gastrointestinal motility.
Management: Stay well hydrated. Dietary adjustments (BRAT diet if needed). Usually self-limiting within the first few weeks of therapy.
Vomiting
Reported in 9–15% of patients, typically during dose escalation. Dose-dependent and generally decreases with continued therapy.
Management: Slow dose titration. Temporarily hold at current dose if vomiting is persistent. Anti-emetics may be used short-term if needed.
Decreased appetite and headache
Reduced appetite (therapeutic effect for weight management) and headache (5–10%) are common during initiation. Constipation (10–15%) may also occur.
Management: Appetite reduction is expected and therapeutic. Headache typically resolves with hydration and time. Constipation managed with adequate fiber and fluid intake.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Liraglutide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Liraglutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Metformin (first-line combination with additive glycemic benefit and no dose adjustment needed — well-studied in LEAD trials) — May be used together under medical guidance.
- Safe:SGLT2 inhibitors such as empagliflozin or dapagliflozin (complementary weight loss and cardiovascular/renal protection through different mechanisms) — May be used together under medical guidance.
- Safe:ACE inhibitors or ARBs (synergistic cardiovascular and renal protection — commonly co-prescribed in LEADER population) — May be used together under medical guidance.
With medications
- Caution:Other GLP-1 receptor agonists (semaglutide, exenatide, dulaglutide) — redundant mechanism with increased adverse effects and no additional benefit — Use with caution—discuss with your healthcare provider.
- Caution:DPP-4 inhibitors (sitagliptin, saxagliptin) — overlapping incretin pathway mechanism; inferior to liraglutide monotherapy in head-to-head trials — Use with caution—discuss with your healthcare provider.
- Caution:Sulfonylureas at full dose — increased hypoglycemia risk requires 50% sulfonylurea dose reduction when adding liraglutide — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Liraglutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-4 (dose titration phase)
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
FDA approved for this use
Onset of effects
Gradual
(3-4 weeks)
How it works
Liraglutide (Victoza/Saxenda) is a once-daily GLP-1 hormone that your pancreas naturally makes—the synthetic version helps your body release insulin when blood sugar is high, makes you feel fuller on less food, and protects your heart.
The deeper mechanism
Liraglutide is a 31-amino acid human GLP-1(7-37) analog with 97% sequence homology to native GLP-1, modified with Arg34 substitution and a C16 palmitic acid side chain conjugated at Lys26 via γ-glutamic acid linker.
The C16 fatty acid modification promotes albumin binding (>98% plasma protein binding), resulting in a longer half-life (~13 hours) enabling once-daily dosing.
Liraglutide activates GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion, suppresses glucagon in hyperglycemic states, delays gastric emptying to reduce postprandial glucose excursions, and activates central GLP-1 receptors to promote satiety and suppress appetite.
Meta-analyses suggest liraglutide provides 10–13% cardiovascular event reduction through multiple mechanisms.
What to expect
Weeks 1-4 (dose titration phase)
What you might notice
- Reduced appetite and early feelings of fullness during meals
- Nausea that typically peaks during the first 1–2 weeks and gradually improves
- Beginning of weight loss (1–2 kg) even during dose titration
- Modest initial improvements in fasting blood glucose
What's normal
- GI side effects (nausea, occasional vomiting, diarrhea) are most common during this phase and expected
- Weight loss at this stage is primarily from reduced caloric intake due to appetite suppression
- Blood glucose improvements begin but full glycemic effect requires higher maintenance doses
- The 5-week titration schedule (Saxenda) or 3-week schedule (Victoza) minimizes GI side effects
What's next
- Continue dose escalation per prescribing schedule if tolerating current dose
- GI side effects should improve as the body adjusts to GLP-1 receptor activation
- Full therapeutic effect will develop over the next several weeks at maintenance dose
Weeks 4-16 (early maintenance phase)
What you might notice
- Steady progressive weight loss of 0.5–1 kg per week
- Significant improvements in HbA1c (typically 0.5–1.0% reduction by week 12)
- GI side effects largely resolved or markedly improved
- Increased satiety between meals and reduced food cravings
What's normal
- Weight loss should be progressing steadily toward the 5–10% target
- For Saxenda: evaluate response at 16 weeks — if <4% body weight loss, discuss continuation
- Blood glucose control improves progressively as maintenance dose is established
- Cardiovascular benefits are building but require long-term therapy for full effect
What's next
- If weight loss and/or glycemic goals are being met, continue maintenance therapy long-term
- Reinforce lifestyle modifications (diet, exercise) that enhance liraglutide efficacy
- Monitor renal function and lipids as secondary cardiometabolic parameters improve
Months 4-12+ (long-term maintenance)
What you might notice
- Weight loss plateau at approximately 5–10% of initial body weight (individual results vary)
- Sustained HbA1c reduction of 0.9–1.6% from baseline
- Improved blood pressure and lipid parameters
- Maintained appetite control and metabolic improvements
What's normal
- Weight loss rate naturally slows after the initial 4–6 months — this is metabolic adaptation, not treatment failure
- Long-term LEADER data shows sustained cardiovascular benefits with continued use over 3.5–5 years
- Some weight regain may occur if therapy is discontinued (typically within months)
- Regular monitoring of HbA1c, renal function, and lipids recommended
What's next
- Continue therapy long-term for sustained cardiometabolic benefits
- Annual assessment of ongoing benefit and tolerability
- Cardiovascular protection continues to accrue with longer duration of therapy
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Liraglutide over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Tested in people
471 registered studies, 25 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 87,455 people took part in the studies that actually administered Liraglutide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Metabolic Surgery for Atrial Fibrillation Elimination
Ali Aminian
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
Talengen Institute of Life Sciences, Shenzhen, P.R. China.
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Liraglutide is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked
What is the difference between Victoza and Saxenda?
Victoza and Saxenda both contain liraglutide but are prescribed for different conditions. Victoza (1.2–1.8 mg daily) is FDA-approved for type 2 diabetes to improve blood sugar control, while Saxenda (3.0 mg daily) is approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. They should not be used together or with any other GLP-1 receptor agonist.
How does liraglutide cause weight loss?
Liraglutide promotes weight loss through two main mechanisms: it activates GLP-1 receptors in the hypothalamus and brainstem to reduce appetite and increase feelings of fullness (satiety), and it delays gastric emptying so food stays in the stomach longer, further promoting satiety. Unlike stimulant-based weight loss drugs, liraglutide works through natural hormonal pathways that regulate hunger.
What was the LEADER trial and why is it significant?
The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was a landmark randomized controlled trial of 9,340 patients with type 2 diabetes and high cardiovascular risk, followed for 3.5–5 years. It demonstrated that liraglutide reduced major adverse cardiovascular events by 13%, cardiovascular death by 22%, and was the first GLP-1 receptor agonist to prove cardiovascular superiority in a large outcomes trial.
Why is there a black box warning about thyroid cancer?
In rodent studies, liraglutide caused thyroid C-cell tumors (including medullary thyroid carcinoma) at doses exceeding clinical use. However, rodents have significantly more GLP-1 receptors on thyroid C-cells than humans, and no cases of medullary thyroid carcinoma attributable to liraglutide have been confirmed in human clinical trials. The black box warning is precautionary, and liraglutide is contraindicated in patients with personal or family history of MTC or MEN2 syndrome.
Can liraglutide be used with insulin?
Yes, liraglutide can be combined with basal insulin (such as insulin glargine or degludec). However, the insulin dose should be reduced when starting liraglutide to minimize hypoglycemia risk. The fixed-ratio combination Xultophy (insulin degludec + liraglutide) is specifically designed for this purpose. Liraglutide should not be combined with prandial (mealtime) insulin without careful medical supervision.
How does liraglutide compare to semaglutide?
Both are GLP-1 receptor agonists from Novo Nordisk, but semaglutide (Ozempic/Wegovy) offers once-weekly dosing and generally greater weight loss (up to 15% body weight at higher doses) compared to liraglutide's daily dosing and 5–10% weight loss. Liraglutide has a longer safety track record (approved since 2010) and more extensive cardiovascular outcomes data. The choice depends on individual patient factors including dosing preference, weight loss goals, and insurance coverage.
Further reading
History & related research
History · since 1983
The Anglerfish Discovery That Launched the Weight-Loss Revolution
From a deep-sea fish to the world's medicine cabinets — follow the 40-year journey of a gut hormone that nobody believed in, a scientist who refused to quit, and the drug that changed how we treat diabetes and obesity forever.
Read the full history of LiraglutideStudied for
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Liraglutide, on one page.